CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
BIA 2-093 (Eslicarbazepine acetate)drug
Likely dose
BIA 2-093 (Eslicarbazepine acetate) 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02170064
NCT02170064Phase 2Completed
CompareCT.gov

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy

Bial - Portela C S.A.·interventional·Posted Jun 23, 2014·Updated Sep 20, 2017

In Brief

A Phase 2 clinical trial evaluating BIA 2-093 (Eslicarbazepine acetate) for Epilepsy. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesRomania
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 23, 2014
Enrollment StartJun 1, 2005
Primary CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.0 years ago

Interventions

BIA 2-093 (Eslicarbazepine acetate)drug

Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route